Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database.
Jianxing ZhouYou ZhengBaohua XuSongjun LongLi-E ZhuYunhui LiuChengliang LiYifan ZhangMaobai LiuXuemei WuPublished in: BMC medicine (2024)
We found no signal of disproportionate reporting of an association between GLP-1RA use and SSIBs. Clinicians need to maintain heightened vigilance on patients premedicated with neuropsychotropic drugs. This contributes to the greater acceptance of GLP-1RAs in patients with type 2 diabetes mellitus or obesity.
Keyphrases
- adverse drug
- end stage renal disease
- ejection fraction
- newly diagnosed
- metabolic syndrome
- rheumatoid arthritis
- type diabetes
- insulin resistance
- peritoneal dialysis
- palliative care
- depressive symptoms
- prognostic factors
- drug induced
- electronic health record
- systemic lupus erythematosus
- weight gain
- physical activity
- adipose tissue
- disease activity
- systemic sclerosis
- interstitial lung disease
- wild type